New Zealand markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.85-1.11 (-7.42%)
At close: 04:00PM EDT
13.89 +0.04 (+0.29%)
After hours: 07:59PM EDT

Novavax, Inc.

700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,543

Key executives

NameTitlePayExercisedYear born
Mr. John Charles Jacobs M.B.A.President, CEO & Director1.33MN/A1967
Mr. John Joseph Trizzino B.S., M.B.A.President & COO670.55kN/A1960
Mr. James Patrick Kelly C.F.A.Executive VP, CFO & Treasurer716.17kN/A1966
Mr. Mark CaseyExecutive VP, Chief Legal Officer & Corporate Secretary137.36kN/A1963
Mr. Richard P. CrowleyExecutive VP & COON/AN/A1957
Dr. Robert Walker M.D.Senior VP, Chief Medical Officer and Interim Head of R&DN/AN/AN/A
Mr. Troy Morgan Esq., J.D.Senior VP & Chief Compliance OfficerN/AN/A1971
Ms. Erika S. TrahanAssociate Director of Investor & Public RelationsN/AN/AN/A
Mr. Ian J. WatkinsExecutive VP & Chief Human Resources OfficerN/AN/A1963
Ms. Silvia Taylor M.B.A.Executive VP and Chief Corporate Affairs & Advocacy OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate governance

Novavax, Inc.’s ISS governance QualityScore as of 1 July 2024 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.